Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia

(2008) Claes Karlsson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

(2008) Carmen D. Schweighofer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma

(2008) John D. Hainsworth et al.   CANCER

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab

(2008) Clive S. Zent et al.   CANCER

Disease burden of chronic lymphocytic leukaemia within the European Union

(2008) Louise Watson et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early–intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

(2008) Clive S. Zent et al.   LEUKEMIA RESEARCH

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

(2008) S. Demko et al.   ONCOLOGIST